CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts

MediaSarah ConnorsVP, Communications and Patient Advocacy(508) 654-2277sarah.connors@cgoncology.com

Investor RelationsLaurence WattsNew Street IR(619) 916-7620IR@cgoncology.com

Grafico Azioni CG Oncology (NASDAQ:CGON)
Storico
Da Ago 2024 a Set 2024 Clicca qui per i Grafici di CG Oncology
Grafico Azioni CG Oncology (NASDAQ:CGON)
Storico
Da Set 2023 a Set 2024 Clicca qui per i Grafici di CG Oncology